The aim of the present study was to clarify the involvement of prostaglandin E(2) (PGE(2)) in nasal congestion in Brown Norway (BN) rats. For this purpose, we studied the effects of PGE(2) receptor (EP(1), EP(2), EP(3) and EP(4)) agonists on nasal congestion and sneezing induced by toluene 2,4-diisocyanate (TDI). Enhanced pause (Penh) was increased 1 h (early phase) and 4 h (late phase) after TDI challenge. Sulprostone (an EP(3) receptor agonist) inhibited the increase of Penh, an index of nasal congestion, in both early and late phase responses. On the other hand, PGE(1) alcohol (an EP(4) agonist) increased Penh in the early phase response. Moreover, sulprostone inhibited sneezing, an immediate response by TDI challenge. These results indicate that EP(3) receptor is responsible for the relief of nasal congestion in both early and late phase responses, and EP(4) receptor is correlated with the development of nasal congestion in the early phase response. In addition, EP(3) receptor also participates in sneezing in allergic rhinitis induced by TDI challenge in BN rats.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1248/bpb.33.64 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Induces Two Types of Dendritic Cell Activation and Effectively Suppresses Onset of the Common Cold: A Randomized, Double-Blind, Placebo-Controlled Trial.
Nutrients
December 2024
Nihonbashi Cardiology Clinic, Kyodo Bldg. #201, 13-4 Nihonbashi Kodenmacho, Chuo-ku, Tokyo 103-0001, Japan.
Background/objectives: GCL1815 is a lactic acid bacterium thought to activate dendritic cells. This randomized, placebo-controlled, double-blind study aimed to evaluate the effects of GCL1815 on human dendritic cells and the onset of the common cold.
Methods: Two hundred participants were divided into two groups and took capsules containing either six billion GCL1815 cells or placebo for 8 weeks.
Xylometazoline-induced change in aspirated nasal nitric oxide detects obstructed paranasal ostia.
J Breath Res
January 2025
Faculty of Medicine and Health Technology, Tampere University, Arvo Ylpön Katu 34, Tampere, 33520, FINLAND.
The concentrations of nasal nitric oxide (nNO) vary in patients with chronic rhinosinusitis (CRS) supposedly depending upon whether the paranasal ostia are open or obstructed. Our aim was to assess whether nNO levels and their response to topical xylometazoline (a local vasoconstrictor used to alleviate nasal congestion) in patients with CRS differ between those with open or obstructed ostia and if the results were altered by the use of nasal corticosteroids. Methodology: Sixty-six patients with CRS (43% with nasal polyps) or recurrent acute rhinosinusitis and 23 healthy controls were included.
View Article and Find Full Text PDFPrevalence of Ear, Nose, and Throat Problems in Saudi Arabia: A Cross-Sectional Study.
Cureus
January 2025
Department of Emergency Medicine, King Faisal Hospital, Makkah, SAU.
Background Ear, nose, and throat (ENT) disorders are common and significantly impact the quality of life. This study aimed to assess the prevalence of ENT problems among the Saudi population and to explore its association with sociodemographic factors, knowledge, and healthcare utilization. Methodology A cross-sectional study was conducted among 405 participants aged 18-80 years across Saudi Arabia.
View Article and Find Full Text PDFSingle-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Nat Med
January 2025
National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; New Cornerstone Science Laboratory; National Clinical Research Center for Respiratory Diseases; Department of Respiratory Medicine, Capital Medical University; Institute of Respiratory Medicine of Capital Medical University; Chinese Academy of Medical Sciences; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.
Suraxavir marboxil (GP681) is an antiviral drug inhibiting the polymerase acidic protein (PA) of RNA polymerase, of influenza. It has shown therapeutic activity against influenza A and B virus infections in preclinical studies. In this multicenter randomized, double-blind, placebo-controlled, phase 3 trial, we aimed to investigate the efficacy and safety of single-dose suraxavir marboxil (40-mg oral dose) in otherwise healthy outpatients aged 5-65 years with uncomplicated influenza unaccompanied by severe issues.
View Article and Find Full Text PDFPredicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers.
World Allergy Organ J
January 2025
Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
Background: The treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) with omalizumab has been well studied based on clinical evaluation. Nevertheless, ideal quantitative or qualitative biomarkers for predicting a different response to biologics urgently need to be explored. We aim to identify potential biomarkers for predicting a good or poor response in patients with refractory CRSwNP.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!